 Alnylam Pharmaceuticals Inc NASDAQ: ALNY has announced detailed data from HELIOS-A Phase 3 study of vutrisiran at 18 months in patients with transthyretin-mediated ATTR amyloidosis. Transthyretin amyloidosis is characterized by the buildup of abnormal deposits of a protein called amyloid amyloidosis in the bodys organs and tissues. 